Is there any Association between the Functional Variants of the NOS3 Gene and Psoriasis?

Introduction: Psoriasis (Ps) is a chronic, immune-mediated inflammatory skin disorder with an incompletely understood etiology. The aim of this study was to investigate the relationship between the suspectibility to Ps and G894T (rs1799983) and variable number tandem repeat (VNTR) variants of the endothelial nitric oxide synthase (NOS3) gene

Association of the TNF-alpha, IL-2, and IL-2RB gene variants with susceptibility to psoriasis in a Turkish cohort

Aim of the study: The aim of this study was to investigate the role TNF-alpha, IL-2, and IL-2RB variants in psoriasis (Ps) and to evaluate the association between these variants and clinical features

Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria

The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at p=0.05. SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related

TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey

Psoriasis is a common inflammatory disease that has a severe impact on quality of life. There is lack of data regarding epidemiological and clinical features of psoriasis patients in Turkey, a country with a population of 76million. The aim of this study was to define the demographic and clinical characteristics, quality of life and treatment patterns of psoriasis patients in Turkey. A cross-sectional observational study was conducted at 40 centers, chosen from geographically diverse locations in Turkey. Patients diagnosed with psoriasis were assessed by investigators who were specialists of dermatology using standardized study questionnaire forms. Dermatology Life Quality Index (DLQI) and EuroQol-5 dimension (EQ-5D) forms were also filled out by each patient. 3971 psoriasis patients were included in this study. 24.2% of plaque psoriasis patients had moderate to severe psoriasis (Psoriasis Area and Severity Index, 10). Mean DLQI was 7.03 +/- 6.02; quality of life was moderately, severely or very severely affected in 49.2% of patients. The most severely affected component of EQ-5D was anxiety/depression. Among all patients, 22.9% were not receiving any treatment, 39.8% were receiving only topical treatment, 11.5% were on phototherapy, 26.1%, were taking conventional systemic agents and 4.1% were on a biologic treatment. 31.3% of psoriasis patients with moderate to severe disease were treated with only topical agents and only 30.5% of moderate to severe psoriasis patients were receiving systemic therapy. Moderate to severe psoriasis has a considerable impact on quality of life. Treatment in Turkey of patients with moderate to severe psoriasis is insufficient

TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey

WOS: 000371889000011PubMed ID: 26365805Psoriasis is a common inflammatory disease that has a severe impact on quality of life. There is lack of data regarding epidemiological and clinical features of psoriasis patients in Turkey, a country with a population of 76million. The aim of this study was to define the demographic and clinical characteristics, quality of life and treatment patterns of psoriasis patients in Turkey. A cross-sectional observational study was conducted at 40 centers, chosen from geographically diverse locations in Turkey. Patients diagnosed with psoriasis were assessed by investigators who were specialists of dermatology using standardized study questionnaire forms. Dermatology Life Quality Index (DLQI) and EuroQol-5 dimension (EQ-5D) forms were also filled out by each patient. 3971 psoriasis patients were included in this study. 24.2% of plaque psoriasis patients had moderate to severe psoriasis (Psoriasis Area and Severity Index, 10). Mean DLQI was 7.03 +/- 6.02; quality of life was moderately, severely or very severely affected in 49.2% of patients. The most severely affected component of EQ-5D was anxiety/depression. Among all patients, 22.9% were not receiving any treatment, 39.8% were receiving only topical treatment, 11.5% were on phototherapy, 26.1%, were taking conventional systemic agents and 4.1% were on a biologic treatment. 31.3% of psoriasis patients with moderate to severe disease were treated with only topical agents and only 30.5% of moderate to severe psoriasis patients were receiving systemic therapy. Moderate to severe psoriasis has a considerable impact on quality of life. Treatment in Turkey of patients with moderate to severe psoriasis is insufficient.PfizerPfizerThis study was sponsored by Pfizer, employees of Pfizer contributed to the design of the study, interpretation of the results and development of the manuscript. Editorial assistance with manuscript development was provided by Susanne Gilbert of ACUMED (New York, NY, USA) and was funded by Pfizer. The authors acknowledge the contributions of the investigators: Dr Esra Ozsoy Adisen, Dr Vahide Baysal Akkaya, Dr Aye Esra Koku Aksu, Dr Hamza Aktas, Dr Aynur Akyol, Dr Sema Altun, Dr Ilknur Altunay, Dr Aysegul Altuntas, Dr E. Esra Arpag, Dr Burcak Bozdemir Aral, Dr Safak Arslan, Dr Gokcen Balci, Dr Emel Bulbul Baskan, Dr Cemal Bilac, Dr Ferihan Uslu Bilgin, Dr Ilgul Bilgin, Dr Omer Calka, Dr Burcin Dogan, Dr Tugba Ekmekci, Dr H. Meral Eksioglu, Dr Sevinc Elinc, Dr Mustafa Teoman Erdem, Dr Bema Sanli Erdogan, Dr Ayten Ferahbas, Dr Gonca Gokdemir, Dr Seyma Celik Gulecol, Dr Asli Gulel, Dr Ulas Guvenc, Dr Asli Hapa, Dr Seval Dogruk Kacar, Dr Basak Kandi, Dr Isin Kilic Karaarslan, Dr Yelda Karincaoglu, Dr Aylin Haskok Kazanci, Dr Sevgi Kilic, Dr Yildiz Kilinc, Dr Saliha Can Kirbas, Dr Rafet Koca, Prof. Dr Mukadder Kocak, Dr Selma Korkmaz, Dr Adem Kosklu, Dr Ergun Kusku, Dr Nurdan Seda Kutlu, Dr Hamdi R. Memisoglu, Dr Ahmet Metin, Dr Inci Mevlitoglu, Dr Ozgul Mustu, Dr Tuba Ozceyhan, Dr Mustafa Ozdemir, Dr Ayes Sebnem Ozkan, Dr Serap Ozturkcan, Dr Hatice Ozyigit, Dr Mustafa Turhan Sahin, Dr Muzaffer Sahin, Dr Mehmet Sakman, Dr Sezai Sasmaz, Dr Neslihan Sendur, Doc. Dr Nilgun Senturk, Dr Gamze Serarslan, Dr Engin Sezer, Dr Funda Tas, Dr Nazan Sengun Taslidere, Dr Nergiz Turan, Dr Muge Turkmen, Dr Isin Zehra Uluc, Dr Cahit Yavuz, Dr I. Halil Yavuz, Dr Savas Yayli, Dr Eylem Yilmaz, Dr Yasar Yilmaz, Dr Tulin Yuksel and Dr Ilknur Yorgun